NCT06963853 Evaluation of Microbial and Endocrinological Parameters in Dialysis Patients With Sepsis
| NCT ID | NCT06963853 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Western Galilee Hospital-Nahariya |
| Condition | Sepsis |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2022-08-16 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2022-08-16 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective study aims to evaluate the diagnostic value and reliability of blood cultures obtained from different sources-central venous catheter (CVC), dialysis machine, and peripheral vein-in hemodialysis patients with suspected catheter-related bloodstream infections (CRBSIs). By comparing the timing and rates of bacterial growth from each site, the study seeks to identify the most accurate and timely method for diagnosing bloodstream infections in this patient population. In addition, the study will assess the dynamics of parathyroid hormone (PTH) levels during acute infections. Specifically, it will investigate whether a significant drop in PTH levels-and the rate of recovery following infection-correlates with adverse outcomes such as infectious complications, cardiovascular morbidity, or 90-day mortality. These findings may offer valuable prognostic insights and support improved monitoring and treatment strategies for dialysis patients experiencing infection.
Eligibility Criteria
Inclusion Criteria: hemodialysis patients over the age of 18 who are hospitalized at the Galilee Medical Center due to sepsis and have provided written informed consent to participate in this study. \- Exclusion Criteria: • Patients with cognitive impairment who are unable to provide informed consent. \-
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06963853 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sepsis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06963853 currently recruiting?
Yes, NCT06963853 is actively recruiting participants. Contact the research team at ETTYK@gmc.gov.il for enrollment information.
Where is the NCT06963853 trial being conducted?
This trial is being conducted at Nahariya, Israel.
Who is sponsoring the NCT06963853 clinical trial?
NCT06963853 is sponsored by Western Galilee Hospital-Nahariya. The trial plans to enroll 200 participants.